WO2017104821A1 - 浮遊培養馴化接着型細胞の調製方法、接着型上皮細胞の上皮間葉転換誘導方法、及びそれらの利用 - Google Patents
浮遊培養馴化接着型細胞の調製方法、接着型上皮細胞の上皮間葉転換誘導方法、及びそれらの利用 Download PDFInfo
- Publication number
- WO2017104821A1 WO2017104821A1 PCT/JP2016/087606 JP2016087606W WO2017104821A1 WO 2017104821 A1 WO2017104821 A1 WO 2017104821A1 JP 2016087606 W JP2016087606 W JP 2016087606W WO 2017104821 A1 WO2017104821 A1 WO 2017104821A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- adherent
- epithelial
- alicyclic structure
- mesenchymal transition
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/20—Material Coatings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0668—Mesenchymal stem cells from other natural sources
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F232/00—Copolymers of cyclic compounds containing no unsaturated aliphatic radicals in a side chain, and having one or more carbon-to-carbon double bonds in a carbocyclic ring system
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G61/00—Macromolecular compounds obtained by reactions forming a carbon-to-carbon link in the main chain of the macromolecule
- C08G61/02—Macromolecular compounds containing only carbon atoms in the main chain of the macromolecule, e.g. polyxylylenes
- C08G61/04—Macromolecular compounds containing only carbon atoms in the main chain of the macromolecule, e.g. polyxylylenes only aliphatic carbon atoms
- C08G61/06—Macromolecular compounds containing only carbon atoms in the main chain of the macromolecule, e.g. polyxylylenes only aliphatic carbon atoms prepared by ring-opening of carbocyclic compounds
- C08G61/08—Macromolecular compounds containing only carbon atoms in the main chain of the macromolecule, e.g. polyxylylenes only aliphatic carbon atoms prepared by ring-opening of carbocyclic compounds of carbocyclic compounds containing one or more carbon-to-carbon double bonds in the ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/02—Form or structure of the vessel
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
Definitions
- the present invention relates to a method for preparing adherent cells adapted to suspension culture.
- the present invention also relates to a method for inducing epithelial-mesenchymal transition of adhesive epithelial cells.
- a biopharmaceutical is a recombinant pharmaceutical produced by genetic engineering techniques.
- recombinant medicines those containing as a component an antibody used for cancer treatment or rheumatism treatment, or a protein such as erythropoietin (EPO), which is a hormone for increasing red blood cells, are known.
- EPO erythropoietin
- recombinant drugs have not been widely spread because they are administered in large amounts for treatment and can be expensive to produce. Therefore, raising productivity is an issue.
- Recombinant pharmaceuticals are, for example, in recombinant CHO cells prepared by introducing a gene of a target protein into adherent cells such as CHO (Chinese hamster ovary) cells and proliferating in a floating state. Produced by biosynthesis of the protein of interest.
- adherent cells such as CHO (Chinese hamster ovary) cells
- proliferating in a floating state Produced by biosynthesis of the protein of interest.
- adherent cells such as CHO (Chinese hamster ovary) cells
- proliferating in a floating state Produced by biosynthesis of the protein of interest.
- adherent cells such as CHO (Chinese hamster ovary) cells
- Patent Document 1 discloses that a gene having a gene encoding a target protein and a plasmid having a dihydrofolate reductase gene are introduced into a CHO cell, and the resulting recombinant CHO cell is obtained.
- a method is described in which recombinant CHO cells are cultured in a suspended state by repeating the culture under conditions where the cell density is lower than usual.
- this method repeats the culture until the CHO cells are brought into a floating state, a long time of about 8 weeks is required.
- the subculture period becomes long, the labor and cost for managing and confirming the state of gene mutation, cell alteration, and the like will increase.
- Patent Document 2 discloses that a recombinant CHO cell in which a human antithrombin gene and a dihydrofolate reductase gene are incorporated into a dihydrofolate reductase gene-deficient cell and is suspended is cultured using a hollow fiber culture apparatus.
- a method for producing human antithrombin while suspending the cells is described.
- this method has a problem in terms of cost because a device incorporating a hollow fiber is complicated and expensive.
- the hollow fiber size was increased for mass culture, medium exchange at both ends of the hollow fiber was not uniform, and the medium was likely to be non-uniform. As a result, the pH of the medium changes and stress is applied to the cells in the hollow fiber, which may reduce the productivity of the target protein.
- epithelial-mesenchymal transition Transformation
- EMT epithelial-mesenchymal transition
- epithelial-mesenchymal transition marker Such a protein is called an epithelial-mesenchymal transition marker, and there are a protein whose expression level increases (up regulation) and a protein whose expression level decreases (down regulation) due to induction of epithelial-mesenchymal transition.
- N-cadherin or vimentin is known as an expression level increasing
- E-cadherin or cytokeratin is known as an expression level decreasing (Patent Document 3).
- epithelial-mesenchymal transition is induced by growth factors such as TGF
- growth factors such as TGF are known as epithelial-mesenchymal transition-inducing factors (Non-patent Document 1).
- the present invention has been made in view of such circumstances, and does not require special operation of the adherent cells, and does not die even in a floating state, and a method for preparing an adherent cell adapted to suspension culture, Method for producing nucleic acid or protein using adhesion-type cells conditioned to suspension culture prepared by the method, suspension culture acclimation promoter for adhesion-type cells composed of polymer molded products containing alicyclic structures, and adhesion-type cells to suspension culture It is an object of the present invention to provide a container for acclimation to suspension culture of adherent-type cells, and use of an alicyclic structure-containing polymer molded body for acclimation.
- the present invention also relates to a method for inducing epithelial-mesenchymal transition in the cells by simply contacting the adhesive epithelial cells, a method for producing a nucleic acid or protein using cells that have undergone epithelial-mesenchymal transition by the method, alicyclic Adhesive epithelial cell epithelial-mesenchymal transition inducer comprising structure-containing polymer molded product, use of alicyclic structure-containing polymer molded product for inducing epithelial-mesenchymal transition of adhesive epithelial cells, and adhesive epithelial cell
- An object is to provide a container for inducing epithelial-mesenchymal transition.
- the present inventor has cultivated an adhesion-type cultured cell in a state of being in contact with an alicyclic structure-containing polymer molded product, thereby originally producing an extracellular matrix that is a scaffold. It has been found that the required adherent cells can be grown in a suspension culture system, that is, the adherent cells can be acclimatized, and the present invention relating to the suspension acclimatization of adherent cells has been completed. Furthermore, the present inventors have found that the cells are converted into properties like mesenchymal cells by contacting the polymer molded product containing an alicyclic structure, and the epithelial-mesenchymal transition of the adhesive epithelial cells. The present invention related to induction has been completed.
- a method for inducing mesenchymal transition, (16) an epithelial-mesenchymal transition inducer for adhesive epithelial cells, and (18), (19) a container for inducing epithelial-mesenchymal transition of adhesive epithelial cells are provided.
- a method for preparing adherent cells adapted to suspension culture comprising a step of culturing adherent cells in contact with an alicyclic structure-containing polymer molded article.
- Production method. (7) A suspension culture acclimatization promoter for adherent-type cells comprising an alicyclic structure-containing polymer molded article. (8) Use of an alicyclic structure-containing polymer molded product for acclimating adherent cells to suspension culture in a liquid medium. (9) A container for acclimatization of suspension culture of adherent cells, wherein at least the bottom surface is made of an alicyclic structure-containing polymer molded product. (10) The suspension culture acclimatization container according to (9), wherein the alicyclic structure-containing polymer is a saturated norbornene polymer.
- a method for inducing epithelial-mesenchymal transition comprising a step of culturing adhesive epithelial cells in contact with an alicyclic structure-containing polymer molded product.
- a nucleic acid or protein encoded by a foreign gene is cultured by culturing adherent cells that have undergone epithelial-mesenchymal transition by the method for inducing epithelial-mesenchymal transition according to any one of (12) to (14). Production method.
- An epithelial-mesenchymal transition inducer for adhesive epithelial cells comprising an alicyclic structure-containing polymer molded product.
- FIG. 1 is a graph showing the results of counting the number of EPO-producing CHO cells pre-cultured by the method of the present invention.
- FIG. 2 shows the total number of cells with respect to the number of days elapsed when all cells after preculture mainly composed of CHO cells adapted to suspension culture prepared by the method of the present invention were cultured in the suspension culture system. It is a graph.
- FIG. 3 shows the average doubling time of each precultured sample in the first to third days of culture (live cell growth phase) calculated from the total cell data cultured in the suspension culture system by the method of the present invention. It is a graph to show.
- the method of the present invention is characterized in that the adherent cells are cultivated in contact with the alicyclic structure-containing polymer molded product, thereby acclimatizing the adherent cells to suspension culture in a liquid medium.
- This is a method for preparing adherent cells.
- adherent cells are acclimated to suspension culture, the adherent cells are adapted to the culture environment, so compared to the average doubling time of suspension culture of adherent cells that are not suspended.
- the adherent cells thus obtained have a shorter average doubling time.
- the adherent cell according to the present invention is not particularly limited, and can be arbitrarily selected according to the purpose.
- an adherent cell refers to a cell that can survive and proliferate by adhering to an extracellular matrix under normal culture conditions.
- Adhesive cells include epithelial cells and fibroblasts.
- cells that have been subjected to genetic engineering treatment, such as genetically modified adhesive cells, in which a foreign gene is incorporated into these cells may be used.
- Specific examples of adherent cells include CHO cells, VERO cells, NIH3T3 cells, HEK293 cells, and the like. Among these, CHO cells are preferable because they are easy to acclimate to floating.
- a cell that can express a foreign gene by transduction using a phage or plasmid vector or the like is used for the adherent cell.
- the cells used in the method for inducing epithelial-mesenchymal transition of the present invention include single-layered squamous epithelial cells, multi-layered squamous epithelial cells, columnar epithelial cells, pili (multi-row pili) epithelial cells, transition cells Epithelial cells classified into epithelial cells, cubic epithelial cells, and the like, and epithelial cell-like cells having the same form as these.
- CHO cells and HEK293 cells are examples of epithelial cells.
- the foreign gene can be arbitrarily selected according to the purpose. Specifically, erythropoietin (hereinafter referred to as “EPO”), interferon ( ⁇ , ⁇ , ⁇ ), granulocyte colony stimulating factor G-CSF, interleukin, granulocyte macrophage / colony stimulating factor GM-CSF, human growth hormone
- EPO erythropoietin
- ⁇ , ⁇ , ⁇ interferon
- G-CSF interleukin
- granulocyte macrophage / colony stimulating factor GM-CSF human growth hormone
- a gene encoding a protein such as insulin, glucagon HGF, blood coagulation factor VIII, a biologically active protein such as a cytokine or a hormone such as a human-type antibody
- RNA of a specific target eg, cancer cell
- miR-369 A gene encoding nucleic acid (RNA) such as microRNA and its precursor, which inhibits synthesis and is expected as
- a liquid medium When culturing cells, a liquid medium is used.
- a medium having a pH buffering action having an osmotic pressure suitable for cells, containing nutrient components of cells, and not toxic to cells is used.
- the component exhibiting pH buffering action include tris hydrochloride, various phosphates, and various carbonates.
- the osmotic pressure of the liquid medium is usually adjusted using an aqueous solution in which the concentrations of potassium ions, sodium ions, calcium ions, glucose and the like are adjusted so as to be almost the same as the osmotic pressure of the cells.
- aqueous solution examples include physiological saline such as phosphate buffered saline, Tris buffered saline, and HEPES buffered saline; Ringer's solution such as lactated Ringer's solution, acetated Ringer's solution, and bicarbonated Ringer's solution; It is done.
- the nutrient component of the cell include amino acids, nucleic acids, vitamins, minerals and the like.
- various commercial products such as RPMI-1640, HAM, ⁇ -MEM, DMEM, EMEM, F-12, F-10, and M-199 can be used.
- additives can also be mix
- additives include inducers such as proteins, low molecular compounds having differentiation-inducing activity, minerals, metals, and vitamin components.
- Additives used include ligands, agonists and antagonists that act on receptors on the cell surface; ligands, agonists and antagonists of nuclear receptors; extracellular matrices such as collagen and fivenectin; part of the extracellular matrix or Simulated compounds; components that act on proteins involved in intracellular signal transduction pathways; components that act on enzymes of primary or secondary metabolism in cells; influences the expression of genes in the nucleus or mitochondria in cells Components to be given; DNA and RNA that can be introduced into cells in combination with viral vectors and the like. These additives can be used alone or in combination of two or more.
- the cell culture conditions are not particularly limited, and can be appropriately determined according to the cells to be used and the purpose.
- the cells can be cultured using a humidified thermostat having a carbon dioxide concentration of about 5% and a constant temperature in the range of 20 ° C. to 37 ° C.
- the alicyclic structure-containing polymer molded product used in the present invention is formed by molding an alicyclic structure-containing polymer into an arbitrary shape.
- the alicyclic structure-containing polymer is a resin having an alicyclic structure in the main chain and / or side chain. Especially, what contains an alicyclic structure in a principal chain from viewpoints of mechanical strength, heat resistance, etc. is preferable.
- Examples of the alicyclic structure include a saturated cyclic hydrocarbon (cycloalkane) structure and an unsaturated cyclic hydrocarbon (cycloalkene) structure. From the viewpoints of mechanical strength, heat resistance and the like, a cycloalkane structure or a cycloalkene structure is preferable, and among them, one having a cycloalkane structure is most preferable.
- the number of carbon atoms constituting the alicyclic structure is not particularly limited, but is usually 4 to 30, preferably 5 to 20, and more preferably 5 to 15. When the number of carbon atoms constituting the alicyclic structure is within this range, mechanical strength, heat resistance, and moldability are highly balanced, which is preferable.
- the proportion of the repeating unit having an alicyclic structure in the alicyclic structure-containing polymer may be appropriately selected according to the purpose of use, but is usually 30% by weight or more, preferably 50% by weight or more, more preferably 70% by weight. %. If the proportion of the repeating unit having an alicyclic structure in the alicyclic structure-containing polymer is excessively small, the heat resistance is inferior, which is not preferable.
- the remainder other than the repeating unit having an alicyclic structure in the alicyclic structure-containing polymer is not particularly limited and is appropriately selected according to the purpose of use.
- alicyclic structure-containing polymer examples include (1) norbornene polymer, (2) monocyclic olefin polymer, (3) cyclic conjugated diene polymer, and (4) vinyl alicyclic carbonization.
- examples thereof include hydrogen polymers and hydrides of (1) to (4).
- hydrides of norbornene polymers are preferable from the viewpoints of heat resistance, mechanical strength, and the like.
- Norbornene polymer and hydride thereof Norbornene polymer is obtained by polymerizing norbornene monomer which is a monomer having a norbornene skeleton, which is obtained by ring-opening polymerization and addition. It is roughly divided into those obtained by polymerization.
- Examples of the ring-opening polymer obtained include ring-opening polymers of norbornene monomers, ring-opening polymers of norbornene monomers and other monomers capable of ring-opening copolymerization, and these A hydride etc. are mentioned.
- Examples of the polymer obtained by addition polymerization include addition polymers of norbornene monomers and addition polymers of norbornene monomers and other monomers copolymerizable therewith.
- the saturated norbornene-based polymer is preferable from the viewpoints of heat resistance, mechanical strength, etc., and preferably has no polar group because the cells easily float.
- norbornene monomers examples include bicyclo [2.2.1] hept-2-ene (common name: norbornene), 5-methyl-bicyclo [2.2.1] hept-2-ene, 5,5- Dimethyl-bicyclo [2.2.1] hept-2-ene, 5-ethyl-bicyclo [2.2.1] hept-2-ene, 5-ethylidene-bicyclo [2.2.1] hept-2- Ene, 5-vinyl-bicyclo [2.2.1] hept-2-ene, 5-propenylbicyclo [2.2.1] hept-2-ene, 5-methoxycarbonyl-bicyclo [2.2.1] Bicyclic such as hepta-2-ene, 5-cyanobicyclo [2.2.1] hept-2-ene, 5-methyl-5-methoxycarbonyl-bicyclo [2.2.1] hept-2-ene Monomer; tricyclo [4.3.0 1,6 .
- deca-3,7-diene (common name: dicyclopentadiene), 2-methyldicyclopentadiene, 2,3-dimethyldicyclopentadiene, 2,3-dihydroxydicyclopentadiene, etc.
- Monomer Tetracyclo [4.4.0.1 2,5 . 1 7,10 ] -3-dodecene (tetracyclododecene), tetracyclo [4.4.0.1 2,5 . 1 7,10 ] -3-dodecene, 8-methyltetracyclo [4.4.0.1 2,5 . 1 7,10 ] -3-dodecene, 8-ethyltetracyclo [4.4.0.1 2,5 .
- dec-3-ene (common name: methanotetrahydrofluorene: 1,4-methano-1, 4,4a, 9a-tetrahydrofluorene), 1,4-methano-8-methyl-1,4,4a, 9a-tetrahydrofluorene, 1,4-methano-8-chloro-1,4,4a, 9a A tetracyclic monomer such as tetrahydrofluorene and 1,4-methano-8-bromo-1,4,4a, 9a-tetrahydrofluorene;
- monomers capable of ring-opening copolymerization with norbornene monomers include cyclohexene, cycloheptene, cyclooctene, 1,4-cyclohexadiene, 1,5-cyclooctadiene, 1,5-cyclodecadiene, And monocyclic cycloolefin monomers such as 1,5,9-cyclododecatriene and 1,5,9,13-cyclohexadecatetraene.
- These monomers may have one or more substituents. Examples of the substituent include an alkyl group, an alkylene group, an aryl group, a silyl group, an alkoxycarbonyl group, and an alkylidene group.
- ⁇ -olefin monomers having 2 to 20 carbon atoms such as ethylene, propylene, 1-butene, 1-pentene and 1-hexene; cyclobutene, cyclopentene, cyclohexene, cyclooctene, tetracyclo [9.2.1.0 2,10.
- Cycloolefin monomers such as 0 3,8 ] tetradeca-3,5,7,12-tetraene (also referred to as 3a, 5,6,7a-tetrahydro-4,7-methano-1H-indene);
- Non-conjugated diene monomers such as 4-hexadiene, 4-methyl-1,4-hexadiene, 5-methyl-1,4-hexadiene, 1,7-octadiene, and the like.
- ⁇ -olefin monomers are preferable, and ethylene is more preferable.
- These monomers may have one or more substituents. Examples of the substituent include an alkyl group, an alkylene group, an aryl group, a silyl group, an alkoxycarbonyl group, and an alkylidene group.
- a ring-opening polymer of a norbornene-based monomer, or a ring-opening polymer of a norbornene-based monomer and another monomer capable of ring-opening copolymerization with a monomer component is a known ring-opening polymerization. It can be obtained by polymerization in the presence of a catalyst.
- the ring-opening polymerization catalyst include a catalyst comprising a metal halide such as ruthenium or osmium, a nitrate or an acetylacetone compound, and a reducing agent, or a metal halide or acetylacetone such as titanium, zirconium, tungsten, or molybdenum.
- a catalyst comprising a compound and an organoaluminum compound can be used.
- the ring-opening polymer hydride of a norbornene-based monomer is usually obtained by adding a known hydrogenation catalyst containing a transition metal such as nickel or palladium to the polymerization solution of the ring-opening polymer, and then adding a carbon-carbon unsaturated bond. Can be obtained by hydrogenation.
- a catalyst composed of a titanium, zirconium or vanadium compound and an organoaluminum compound can be used.
- Monocyclic cyclic olefin polymer for example, an addition polymer of a monocyclic olefin monomer such as cyclohexene, cycloheptene, or cyclooctene can be used. it can.
- Cyclic conjugated diene polymer and hydride thereof Cyclic conjugated diene polymer and hydride thereof include, for example, cyclic conjugated diene monomers such as cyclopentadiene, cyclohexadiene, 1, 2- or 1, Examples include 4-addition polymerized polymers and hydrides thereof.
- Vinyl alicyclic hydrocarbon polymer and its hydride include, for example, vinyl alicyclic hydrocarbon monomers such as vinyl cyclohexene and vinyl cyclohexane. A polymer and a hydride thereof; a hydride of an aromatic ring portion of a polymer of a vinyl aromatic monomer such as styrene or ⁇ -methylstyrene; and the like.
- the vinyl alicyclic hydrocarbon polymer may be a copolymer with other monomers copolymerizable with these monomers. These alicyclic structure-containing polymers can be used alone or in combination of two or more.
- an alicyclic structure containing polymer Although there is no special restriction
- the glass transition temperature of the alicyclic structure-containing polymer may be appropriately selected depending on the purpose of use, but is usually 50 to 300 ° C, preferably 100 to 280 ° C, particularly preferably 115 to 250 ° C, and more preferably 130. ⁇ 200 ° C. When the glass transition temperature is within this range, heat resistance and molding processability are highly balanced and suitable. In the present invention, the glass transition temperature is measured based on JIS K7121.
- a compounding agent usually used in thermoplastic resin materials for example, a soft polymer, an antioxidant, an ultraviolet absorber, a light stabilizer, a near infrared absorber, a release agent. Coloring agents such as dyes and pigments, plasticizers, antistatic agents, fluorescent whitening agents, and other compounding agents can be added in amounts usually employed.
- the alicyclic structure-containing polymer may be mixed with another polymer other than the soft polymer (hereinafter simply referred to as “other polymer”).
- the amount of the other polymer mixed with the alicyclic structure-containing polymer is usually 200 parts by weight or less, preferably 150 parts by weight or less, more preferably 100 parts by weight with respect to 100 parts by weight of the alicyclic structure-containing polymer. It is as follows. If the proportion of various compounding agents and other polymers to be blended with the alicyclic structure-containing polymer is too high, cells will not float easily, so all are blended within the range that does not impair the properties of the alicyclic structure-containing polymer. It is preferable.
- the mixing method with the compounding agent and other polymers is not particularly limited as long as the compounding agent is sufficiently dispersed in the polymer. Moreover, there is no special restriction
- a blending method for example, a method of kneading a resin in a molten state using a mixer, a single-screw kneader, a twin-screw kneader, a roll, a Brabender, an extruder, etc., after dissolving and dispersing in an appropriate solvent, Examples include a method of removing the solvent by a coagulation method, a casting method, or a direct drying method.
- a biaxial kneader after kneading, it is usually extruded in a rod shape in a molten state, cut into an appropriate length with a strand cutter, and pelletized in many cases.
- the molding method of the alicyclic structure-containing polymer can be arbitrarily selected according to the shape of the alicyclic structure-containing polymer molded product used when contacting the cells.
- molding methods include injection molding, extrusion molding, cast molding, inflation molding, blow molding, vacuum molding, press molding, compression molding, rotational molding, calendar molding, and rolling molding. , Cutting molding method, spinning and the like, and these molding methods can be combined, or post-treatment such as stretching can be carried out as necessary after molding.
- the shape of the polymer molded product containing an alicyclic structure in contact with cells there is no particular limitation on the shape of the polymer molded product containing an alicyclic structure in contact with cells, and examples thereof include a plate shape and a sheet shape. The surface may be flat or uneven. Good. Furthermore, the container which contains the molded body of such a shape as a part of a structural member may be sufficient, the container comprised entirely with the alicyclic structure containing polymer molded body, and an alicyclic ring may be sufficient as it. The container comprised with the laminated body of a structure containing polymer molded object and another polymer molded object may be sufficient. Specific container shapes include culture containers such as dishes, plates, bags, tubes, scaffolds, cups, and jar fermenters.
- the alicyclic structure-containing polymer molded article thus obtained is the suspension culture acclimatization promoter of the present invention having a function of promoting the adaptation of adherent cells to suspension culture.
- the molded body in order to bring the molded body into contact with the cultured cells, the molded body is usually sterilized.
- a sterilization method there is no particular limitation on the sterilization method, and a known sterilization method can be selected according to the shape of the molded body and the cells used.
- a heating method such as a high-pressure steam method or a dry heat method
- a radiation method that irradiates radiation such as ⁇ rays or electron beams
- an irradiation method that irradiates high frequency
- a gas method in which a gas such as ethylene oxide gas (EOG) is brought into contact Examples of the method generally used in the medical field include a filtration method using a sterilizing filter.
- the gas method is preferable because the change in the surface state is small.
- the alicyclic structure-containing polymer molded product used in the present invention is only required to have at least the surface in contact with the cells formed of the alicyclic structure-containing polymer, and the whole is formed from the alicyclic structure-containing polymer. Not necessarily.
- the water contact angle of the surface of the alicyclic structure-containing polymer molded product that contacts the cells is usually 85 ° to 110 °, preferably 85 ° to 105 °, preferably 85 ° to 100 °. It is particularly preferred.
- the surface of these molded bodies can be subjected to general surface treatments other than sterilization purposes, such as plasma treatment, corona discharge treatment, ozone treatment, and ultraviolet irradiation treatment.
- general surface treatments other than sterilization purposes, such as plasma treatment, corona discharge treatment, ozone treatment, and ultraviolet irradiation treatment.
- the cost generated by performing these surface treatment operations can be suppressed; the cleanliness may be impaired by partial decomposition of the surface of the formed body accompanying the surface treatment; the ability of cells to float or epithelial mesenchyme It is preferable that these surface treatment operations are not substantially performed for reasons such as the possibility that the conversion ability is lowered;
- “substantially do not perform these surface treatment operations” means that these surface treatment operations are not performed, or even if a surface treatment operation is performed, the surface defined by the following formula
- the change rate [X (%)] of the water contact angle on the surface of the molded body after the treatment operation is within ⁇ 20%, preferably within ⁇ 10% Means that.
- any method may be adopted depending on the shape of the alicyclic structure-containing polymer molded product.
- a cell such as a petri dish, a bag, a bottle or the like having at least one surface formed of an alicyclic structure-containing polymer is used to attach cells to the surface formed of the alicyclic structure-containing polymer. Incubate as before. At the beginning of seeding, the cells that have adhered to the surface formed of the polymer containing the alicyclic structure naturally detach in a few days and survive in a floating state. That is, the cells that survive in this floating state are adherent cells that have been adapted to suspension culture.
- Adhesive cells acclimated to suspension culture by the method of the present invention may form a cell mass when static culture is continued as it is, but dissociated by shaking in a normal suspension culture system, It can be used as an adherent cell adapted to a single suspension culture.
- the culture method of the present invention can be cultured in a suspended state at a high density even in the case of an adherent cell, it is preferably used when producing nucleic acid or protein in the cell. .
- the protein can be produced in large quantities by contacting the cell with an alicyclic structure-containing polymer molded product.
- the adherent cells in contact with the alicyclic structure-containing polymer molded article have enhanced transcription amounts of epithelial-mesenchymal transition factors such as TGF, HGF, and FGF, decreased E-cadherin, N-cadherin and vimentin.
- epithelial-mesenchymal transition marker such as an increase in. That is, as described above, the epithelial-mesenchymal transition can be induced in the adherent cells by culturing the adherent epithelial cells in contact with the alicyclic structure-containing polymer molded product. That is, the alicyclic structure-containing polymer molded product functions as an epithelial-mesenchymal transition agent.
- the alicyclic structure-containing polymer molding is a culture vessel, no special operation is required, and epithelial-mesenchymal transition can be caused only by culturing using this vessel.
- Plasmid pLXRN-EPO is constructed by inserting the EPO gene sequence into the expression gene insertion site of the vector pLXRN (manufactured by Chlontech) containing a gene resistant to antibiotic G418. did. The EPO gene in the constructed plasmid was confirmed by analyzing its base sequence. Next, virus particles containing the EPO gene were prepared by transducing the constructed plasmid pLXRN-EPO and the plasmid pVSV-G (Clontech) into package cells GP293T cells (Clontech). In addition, Lipofectamine (manufactured by Invitrogen) was used as a gene introduction reagent for the introduction of plasmid pLXRN-EPO into cells, and the gene introduction was performed according to the manufacturer's manual.
- the GP293T cells subjected to the gene transfer operation are cultured, the culture supernatant is removed, filtered, and 8 ⁇ g / ml polybrene (manufactured by Santacruz) is added to the culture containing virus particles retaining the EPO gene.
- a clear sample was prepared.
- the virus retaining the EPO gene The particles were infected with CHO cells. After 8 hours of incubation, the culture medium for CHO cells was changed to a culture operation for CHO cells producing recombinant EPO.
- Viral infection was confirmed by genomic PCR as follows. First, using Instagene (manufactured by BioRad), the genome was extracted from the infected CHO cells, and it was confirmed by PCR that the pLXRN-EPO sequence was introduced into the genome. Primers used for PCR were pLXRN-seq-F (5′-CGCCCTCCGTCTGAATTTT) and pLXRN-seq-R (TCCCTATGCAAAAGCGAAAC). In order to select CHO cells infected with the virus and having the EPO gene incorporated in the genome, antibiotic G418 is added to the medium, the culture is maintained, and antibiotic E418 resistant CHO cells are selected by drug selection. Producing CHO cells (hereinafter referred to as EPO producing CHO cells) were selected.
- Example 1 As an alicyclic structure-containing polymer, a norbornene-based ring-opening polymer hydride [ZEONEX (registered trademark) 790R, manufactured by Nippon Zeon Co., Ltd .; hereinafter simply referred to as “790R”] is used to produce a dish having a diameter of 3 cm by injection molding. Was made. Hereinafter, this dish is referred to as “790R dish”. The water contact angle of the bottom surface (the side in contact with the cells) of the 790R dish was 90 °.
- EPO-producing CHO cells were seeded at 0.624 ⁇ 10 4 cells / cm 2 using a 790R dish as a culture container and Ham medium containing 10% fetal bovine serum as a liquid medium, and 5% CO Cultivation was performed for 7 days under conditions of 2 atmospheres and 37 ° C. (Counting the number of cells) The number of cells adhering to floating cells was counted by the following method. Floating cells: The culture supernatant was removed and centrifuged, and only the culture supernatant was removed, and trypan blue was allowed to act on the resulting cell components. After reacting for about 3 minutes, the sample was stained with trypan blue to count the number of live and dead cells. A cell number measuring device was used for the measurement.
- Adherent cells The culture supernatant was removed, washed with physiological saline, and then detached from the dish by trypsin treatment. After detachment, these cell samples were stained with trypan blue in a serum-containing culture medium to count the number of live and dead cells. For the measurement, the same apparatus was used.
- Example 1 In Example 1, instead of the 790R dish, the culture was performed in the same manner as in Example 1 except that a polystyrene dish [Falcon (registered trademark) dish (model number 353001, manufactured by Becton Dickinson)] was used. The cell number was counted.
- a polystyrene dish [Falcon (registered trademark) dish (model number 353001, manufactured by Becton Dickinson)] was used. The cell number was counted.
- Example 1 and Comparative Example 1 which are pre-culture steps, are shown in FIG.
- the pre-culture period 7 days after seeding
- the 790R dish the appearance of floating EPO-producing CHO cells of about 80% of the total number of cells was observed, and most of them were living cells.
- the polystyrene dish most of the cells were adhered to the bottom surface, and the floating cells existed as one cell alone, and most of them were dead.
- Example 2 Floating EPO-producing CHO cells that appeared in the 790R pre-dish culture step and EPO-producing CHO cells that were still attached were collected in tubes.
- the culture supernatant in the dish was removed, washed with physiological saline, and then detached and collected from the dish by trypsin treatment.
- Each cell was mixed in a sterilized tube, and after centrifugation, the culture medium was removed and only the cell components were suspended in fresh medium.
- the culture medium in which the cells were suspended was added to the culture vessel of the suspension culture apparatus (Able), and suspension culture was started.
- Example 2 In Example 2, except that a polystyrene dish was used in the pre-culture step, the same operation as in Example 2 was performed to start suspension culture.
- Example 2 and Comparative Example 2 which are suspension culture processes, are shown in FIG.
- the EPO-producing CHO cells pre-cultured in the 790R dish are more proliferating than the EPO-producing CHO cells pre-cultured in the polystyrene dish, and the cell sample pre-cultured in the 790R dish is a sample adapted to the floating cell system. It is believed that there is.
- the average doubling time of the adherent cells statically cultured in the polystyrene dish was 15.6 hours, which was the fastest compared.
- the cell sample pre-cultured in the 790R dish has a faster average doubling time than the cell sample pre-cultured in the polystyrene dish, and the cell sample pre-cultured in the 790R dish acclimated to the suspension culture. It is thought that it was converted to the state.
- Example 3 The CHO cells in the culture vessel after 8 days of culture were collected by the same method as in Example 1 and the CHO cells in the culture vessel after 8 days of culture were collected by the same method as in Comparative Example 1, and all the collected cells were collected by Trizol ( Dissolved in Invitrogen). RNA was collected from the lysed sample. The collection method followed the product manual. Subsequently, the recovered RNA was analyzed by (HiSeq (registered trademark), manufactured by Illumina). The experiment was performed twice, changing the NGS analysis conditions. Both analyzes were performed by the paired-end method. Each of the Read numbers was about 30 million or 50 million.
- TGF, HGF, and FGF which are epithelial-mesenchymal transition inducers, is enhanced in the cell sample cultured in the 790R dish compared to the cell sample cultured in the polystyrene dish. I understand.
- the cell samples cultured in the 790R dish had less epithelial-mesenchymal transition markers E-cadherin and cytokeratin than the cell samples cultured in the polystyrene dish, and N-cadherin and vimentin. , And fibronectin is increased.
- Tables 1 and 2 suggest that cells cultured by the method of the present invention were induced to undergo epithelial-mesenchymal transition.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Clinical Laboratory Science (AREA)
- Sustainable Development (AREA)
- Rheumatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
Description
しかしながら、組み換え医薬品は、治療のために投与する量が多く、また、生産するための費用が高いことがあり、十分に普及するには至っていない。したがって、生産性を上げることが課題となっている。
しかしながら、この方法は、CHO細胞を浮遊状態にするまで培養を繰り返すものであるため、8週間程度という長い時間が必要になる。また、継代培養期間が長くなると、遺伝子の変異や細胞の変質等の状態を管理し、確認する手間と費用が増加することとなる。
しかしながら、この方法には、ホローファイバーを組み込んだ装置が複雑で高価であるため、費用面での問題があった。また、大量培養のためにホローファイバーサイズを大きくすると、ホローファイバーの両端での培地交換が均等ではなく、培地が不均一になりやすかった。この結果、培地のpH等が変化し、ホローファイバー内の細胞にストレスがかかるため、目的のタンパク質の生産性が低下するおそれがあった。
本発明は、かかる実情に鑑みてなされたものであり、接着型細胞を特殊な操作を要さずに、浮遊状態でも死滅することのない、浮遊培養に馴化した接着型細胞の調製方法、当該方法で調整された浮遊培養に馴化した接着型細胞を用いた核酸又はタンパク質の生産方法、脂環構造含有重合体成形体からなる接着型細胞の浮遊培養馴化促進剤、接着型細胞を浮遊培養に馴化させるための脂環構造含有重合体成形体の使用、及び接着型細胞の浮遊培養馴化用容器を提供することを目的とする。
また本発明は、接着型上皮細胞を接触させるのみの操作で該細胞に上皮間葉転換を誘導する方法、当該方法で上皮間葉転換された細胞を用いた核酸又はタンパク質の生産方法、脂環構造含有重合体成形体からなる接着型上皮細胞の上皮間葉転換誘導剤、接着型上皮細胞を上皮間葉転換誘導させるための脂環構造含有重合体成形体の使用、及び接着型上皮細胞の上皮間葉転換誘導用容器を提供することを目的とする。
(2)前記接着型細胞が、外来遺伝子を発現する遺伝子組み換えされた接着型細胞である、(1)に記載の接着型細胞の調製方法。
(3)前記外来遺伝子がタンパク質をコードする遺伝子である、(2)に記載の接着型細胞の調製方法。
(4)前記接着型細胞が動物由来の細胞である、(1)~(3)のいずれかに記載の接着型細胞の調製方法。
(5)前記動物由来の細胞がCHO細胞である、(4)に記載の接着型細胞の調製方法。
(7)脂環構造含有重合体成形体からなる接着型細胞の浮遊培養馴化促進剤。
(8)接着型細胞を液体培地中に浮遊培養に馴化させるための、脂環構造含有重合体成形体の使用。
(9)少なくとも底面が脂環構造含有重合体成形体からなるものである接着型細胞の浮遊培養馴化用容器。
(10)前記脂環構造含有重合体が飽和ノルボルネン系重合体である、(9)に記載の浮遊培養馴化用容器。
(12)前記接着型上皮細胞が、外来遺伝子を発現する遺伝子組み換えされた接着型細胞である、(11)に記載の上皮間葉転換の誘導方法。
(13)前記接着型上皮細胞が動物由来の細胞である、(11)または(12)に記載の上皮間葉転換の誘導方法。
(14)前記動物由来の細胞がCHO細胞である、(13)に記載の上皮間葉転換の誘導方法。
(15)前記(12)~(14)のいずれかに記載の上皮間葉転換の誘導方法により、上皮間葉転換した接着型細胞を培養することによる、外来遺伝子によってコードされた核酸又はタンパク質の生産方法。
(17)接着型上皮細胞を上皮間葉転換誘導させるための、脂環構造含有重合体成形体の使用。
(18)少なくとも底面が脂環構造含有重合体成形体からなるものである接着型上皮細胞の上皮間葉転換誘導用容器。
(19)前記脂環構造含有重合体が飽和ノルボルネン系重合体である、(18)に記載の上皮間葉転換誘導用容器。
接着型細胞が浮遊培養に馴化されると、接着型細胞が培養環境に適合するため、浮遊馴化していない接着型細胞を浮遊培養したときの平均倍化時間と比較して、浮遊培養に馴化された接着型細胞は平均倍化時間が短くなる。
本発明において、接着型細胞は、通常の培養条件において、細胞外基質に接着することで生存及び増殖可能な細胞のことをいう。接着型細胞としては、上皮細胞や線維芽細胞が挙げられる。また、これらの細胞に外来遺伝子を組み込んだ、遺伝子組み換えされた接着型細胞などの遺伝子工学処理を施された細胞であっても良い。接着細胞の具体例としては、CHO細胞、VERO細胞、NIH3T3細胞、HEK293細胞などが挙げられる。これらの中でも浮遊馴化のしやすさからCHO細胞が好ましい。
尚、本発明の上皮間葉転換の誘導方法に用いる細胞は、上記接着細胞の内、単層扁平上皮細胞、重層扁平上皮細胞、円柱上皮細胞、線毛(多列線毛)上皮細胞、移行上皮細胞、立方上皮細胞等に分類される上皮細胞やこれらと同様の形態を持つ上皮細胞様の細胞である。上述した具体例の内、CHO細胞やHEK293細胞が上皮細胞の例となる。
こうした組み換え細胞の培養中に脂環構造含有重合体成形体を接触させると、生理活性タンパク質の生産量が増大する。
液体培地としては、通常、pH緩衝作用があり、浸透圧が細胞に好適なものであり、細胞の栄養成分を含み、かつ、細胞に対して毒性がないものが用いられる。
pH緩衝作用を示す成分としては、トリス塩酸塩、各種リン酸塩、各種炭酸塩等が挙げられる。
液体培地の浸透圧調整は、通常、細胞の浸透圧とほぼ同じになるように、カリウムイオン、ナトリウムイオン、カルシウムイオン、グルコース等の濃度を調整した水溶液を用いて行われる。かかる水溶液としては、具体的には、リン酸緩衝生理食塩水、トリス緩衝生理食塩水、HEPES緩衝生理食塩水等の生理食塩水;乳酸リンゲル液、酢酸リンゲル液、重炭酸リンゲル液等のリンゲル液;等が挙げられる。
細胞の栄養成分としては、アミノ酸、核酸、ビタミン類、ミネラル類等が挙げられる。
液体培地としては、RPMI-1640、HAM、α-MEM、DMEM、EMEM、F-12、F-10、M-199等の各種市販品を利用することができる。
用いる添加剤としては、細胞表面の受容体に作用する、リガンド、アゴニスト、アンタゴニスト;核内受容体の、リガンド、アゴニスト、アンタゴニスト;コラーゲンやファイブネクチン等の細胞外マトリックス;細胞外マトリックスの一部分あるいは、模擬した化合物;細胞内の情報伝達経路に関わるタンパク質に作用する成分;細胞内の1次代謝又は2次代謝の酵素に作用する成分;細胞内の核内又はミトコンドリア内の遺伝子の発現に影響を与える成分;ウィルスベクター等と組み合わせて細胞内に導入することができるDNAやRNA;等が挙げられる。
これらの添加剤は一種単独で、あるいは二種以上を組み合わせて用いることができる。
例えば、二酸化炭素濃度が5%程度で、温度が20℃~37℃の範囲で一定に維持された、加湿された恒温器を用いて細胞を培養することができる。
脂環構造含有重合体は、主鎖及び/又は側鎖に脂環構造を有する樹脂である。なかでも、機械的強度、耐熱性等の観点から、主鎖に脂環構造を含有するものが好ましい。
ノルボルネン系重合体は、ノルボルネン骨格を有する単量体であるノルボルネン系単量体を重合してなるものであり、開環重合によって得られるものと、付加重合によって得られるものに大別される。
これらの単量体は、置換基を1種又は2種以上有していてもよい。置換基としては、アルキル基、アルキレン基、アリール基、シリル基、アルコキシカルボニル基、アルキリデン基等が挙げられる。
これらの中でも、ノルボルネン系単量体と付加共重合可能なその他の単量体としては、α-オレフィン系単量体が好ましく、エチレンがより好ましい。
これらの単量体は、置換基を1種又は2種以上有していてもよい。置換基としては、アルキル基、アルキレン基、アリール基、シリル基、アルコキシカルボニル基、アルキリデン基等が挙げられる。
単環の環状オレフィン系重合体としては、例えば、シクロヘキセン、シクロヘプテン、シクロオクテン等の、単環の環状オレフィン系単量体の付加重合体を用いることができる。
(3)環状共役ジエン系重合体及びその水素化物
環状共役ジエン系重合体及びその水素化物としては、例えば、シクロペンタジエン、シクロヘキサジエン等の環状共役ジエン系単量体を1,2-又は1,4-付加重合した重合体及びその水素化物等が挙げられる。
(4)ビニル脂環式炭化水素重合体及びその水素化物
ビニル脂環式炭化水素重合体及びその水素化物としては、例えば、ビニルシクロヘキセン、ビニルシクロヘキサン等のビニル脂環式炭化水素系単量体の重合体及びその水素化物;スチレン、α-メチルスチレン等のビニル芳香族系単量体の重合体の芳香環部分の水素化物;等が挙げられる。ビニル脂環式炭化水素重合体は、これらの単量体と共重合可能な他の単量体との共重合体であってもよい。
これらの脂環構造含有重合体は、それぞれ単独で、あるいは2種以上を組み合わせて用いることができる。
本発明においてガラス転移温度は、JIS K 7121に基づいて測定されたものである。
また、脂環構造含有重合体には、軟質重合体以外のその他の重合体(以下、単に「その他の重合体」という)を混合しても良い。脂環構造含有重合体に混合されるその他の重合体の量は、脂環構造含有重合体100重量部に対して、通常200重量部以下、好ましくは150重量部以下、より好ましくは100重量部以下である。
脂環構造含有重合体に対して配合する各種配合剤やその他の重合体の割合が多すぎると細胞が浮遊し難くなるため、いずれも脂環構造含有重合体の性質を損なわない範囲で配合することが好ましい。
配合剤やその他の重合体との混合方法は、ポリマー中に配合剤が十分に分散する方法であれば、特に限定されない。また、配合順序に格別な制限はない。配合方法としては、例えば、ミキサー、一軸混練機、二軸混練機、ロール、ブラベンダー、押出機等を用いて樹脂を溶融状態で混練する方法、適当な溶剤に溶解して分散させた後、凝固法、キャスト法、又は直接乾燥法により溶剤を除去する方法等が挙げられる。
二軸混練機を用いる場合、混練後は、通常は溶融状態で棒状に押出し、ストランドカッターで適当な長さに切り、ペレット化して用いられることが多い。
具体的な容器の形状としては、ディッシュ、プレート、バッグ、チューブ、スキャホールド、カップ、ジャー・ファーメンター等の培養容器が挙げられる。
そして、こうして得られる脂環構造含有重合体成形体は、接着細胞の浮遊培養への馴化を促進する機能を有する、本発明の浮遊培養馴化促進剤である。
滅菌処理の方法に格別な制限はなく、成形体の形状や用いる細胞に応じて、公知の滅菌処理法選択することができる。例えば、高圧蒸気法や乾熱法等の加熱法;γ線や電子線等の放射線を照射する放射線法や高周波を照射する照射法;酸化エチレンガス(EOG)等のガスを接触させるガス法;滅菌フィルタを用いる濾過法;等、医療分野で一般的に採用される方法が挙げられる。これらの中でも、表面状態の変化が少ないことから、ガス法が好ましい。
この脂環構造含有重合体成形体の細胞と接触する面の水接触角は通常85°以上110°以下であり、85°以上105°以下であることが好ましく、85°以上100°以下であることが特に好ましい。
ここで、水接触角は、公知の全自動接触角計(本願実施例においては、協和界面科学社製「LCD-400S」を使用)を用い、ディッシュ底面をΦ30mmのサークルカッターで切り取って、試料の中心と、そこを中央とする1辺20mmの正方形の頂点4か所、計5か所を測定点とし、液滴の半径rと高さhを求め、tanθ1=h/r、θ=2arctan(h/r)で求められるθである(θ/2法)。
例えば、タンパク質をコードする外来遺伝子を発現することのできる組み換え細胞の培養中に、当該細胞と脂環式構造含有重合体成形体とを接触させることにより、タンパク質を大量に産生させることができる。
即ち、脂環構造含有重合体成形体は、上皮間葉転換剤として機能するものである。脂環構造含有重合体成形体が培養容器である場合、特別な操作を要さず、本容器を用いて培養するだけで上皮間葉転換を起こすことができる。
抗生物質G418への耐性遺伝子を内包するベクターpLXRN(Chlontech社製)の発現遺伝子の挿入サイトに、EPO遺伝子配列を挿入してプラスミドpLXRN-EPOを構築した。構築したプラスミドの中のEPO遺伝子は、その塩基配列解析を行うことにより確認した。
次に、構築したプラスミドpLXRN-EPOとプラスミドpVSV-G(Clontech社製)を、パッケージ細胞であるGP293T細胞(Clontech社製)に形質導入することにより、EPO遺伝子を含有するウイルス粒子を調製した。
なお、細胞へのプラスミドpLXRN-EPOの導入操作のための遺伝子導入試薬として、Lipofectamine(invitorogen社製)を用い、遺伝子導入操作は、メーカーのマニュアルに従った。
続いて、あらかじめ培養したCHO細胞試料の培養液を除いて、上記のEPO遺伝子を保持したウイルス粒子を含む培養上清試料を添加して、8時間培養維持することにより、EPO遺伝子を保持したウイルス粒子をCHO細胞に感染させた。
8時間のインキュベーションの後に、CHO細胞の培養培地に交換を行い、組み換えEPOを産生するCHO細胞の培養操作を行った。
ウイルスが感染し、ゲノムにEPO遺伝子が組み込まれたCHO細胞を選抜するため、抗生物質G418を培地に添加し、培養維持して、抗生物質G418耐性のCHO細胞を薬剤選択することにより、組み換えEPO産生CHO細胞(以下、EPO産生CHO細胞という。)を選抜した。
脂環構造含有重合体として、ノルボルネン系開環重合体水素化物〔ゼオネックス(登録商標)790R、日本ゼオン社製;以下、単に「790R」という〕を用いて、射出成形法により、直径3cmのディッシュを作製した。以下、このディッシュを「790R製ディッシュ」という。790R製ディッシュの底面(細胞と接触する側)の水接触角は、90°であった。
培養容器として790R製ディッシュを使用し、液体培地として10%牛胎児血清を含むHam培地を使用して、EPO産生CHO細胞を0.624×104cells/cm2で播種して、5%CO2雰囲気37℃の条件で7日間培養を行った。
(細胞数の計測)
以下の方法により、浮遊している細胞と接着している細胞の数を計測した。
浮遊している細胞:培養上清を取り出して遠心処理した試料から、培地上清のみを除き、得られた細胞成分にトリパンブルーを作用させた。3分程度反応させた後、試料をトリパンブルー染色して生細胞及び死細胞数を計測した。計測には、細胞数計測装置を用いた。
接着している細胞:培養上清を除去し、生理食塩水で洗浄後、トリプシン処理によりディッシュから細胞を剥離した。剥離後、血清含培養培地で、これら細胞試料をトリパンブルー染色して生細胞及び死細胞数を計測した。計測は、同様に装置を用いた。
実施例1において、790R製ディッシュに代えて、ポリスチレン製ディッシュ〔ファルコン(登録商標)ディッシュ(型番353001、ベクトンデッキンソン社製)〕を使用したことを除き、実施例1と同様にして培養を行い、細胞数を計測した。
前培養(播種後7日)期間に、790R製ディッシュでは、全細胞数に対して8割程度の浮遊しているEPO産生CHO細胞の出現が観察され、大部分が生細胞であった。一方、ポリスチレン製ディッシュでは、大部分は底面に接着している細胞であり、浮遊している細胞は、1個の細胞単独で存在し、かつ、大部分が死滅状態にあった。
790R製ディッシュ前培養工程で出現した浮遊しているEPO産生CHO細胞及び未だ接着しているEPO産生CHO細胞をチューブに回収した。尚、ここで接着している細胞については、ディッシュ中の培養上清を除去し、生理食塩水で洗浄後、トリプシン処理によりディッシュから細胞を剥離・回収した。各々の細胞を滅菌チューブの中に混合し、遠心分離操作後に、培養培地を取り除き、細胞成分のみを新しい培地に懸濁した。細胞が懸濁された培地を浮遊培養装置(エイブル社製)の培養容器に添加し、浮遊培養を開始した。
実施例2において、前培養工程でポリスチレン製ディッシュを使用したことを除き、実施例2と同様に操作を行い、浮遊培養を開始した。
790R製ディッシュで前培養したEPO産生CHO細胞は、ポリスチレン製ディッシュで前培養したEPO産生CHO細胞よりも増殖しており、790R製ディッシュで前培養した細胞試料は、浮遊細胞システムに馴化した試料であると考えられる。
更に、比較のため、ポリスチレン製ディッシュで静置培養した、即ち接着状態で培養されている細胞の平均倍化時間も測定した。
実施例1と同様の方法により8日間培養後の培養容器中のCHO細胞と、比較例1と同様の方法により8日間培養後培養容器中のCHO細胞を回収し、回収した全細胞をTrizol(Invitrogen社製)で溶解した。溶解した試料から、RNAを採取した。採取方法は製品マニュアルに従った。次いで、回収されたRNAを、(HiSeq(登録商標)、Illumina社製)で解析した。
実験はNGS解析条件を変更して2回実施した。両解析とも、paired-end法で実施した。各々Read数は3000万または5000万程度であった。リファレンスとして、公開情報(GCF_000223135.1_CriGri_1.0_ma.fa.fai)を用いた。
得られた転写量のデータを、(CLC Genomics Workbench、CLC bio社製)にてRNA-Seqを解析し、mRNAの転写量をRPKM値として数値化した。
得られたRPKM値を、(CLC Genomics Workbench、CLC bio社製)にてEDGE解析し、790R製ディッシュで培養した細胞群の転写量と、ポリスチレン製ディッシュで培養した細胞群の転写量を比較し、Fold Change値(ポリスチレン製ディッシュでの転写量に対する790R製ディッシュでの転写量の比率)を得た。ここで、Fold Change値が正の整数であれば790R製ディッシュの転写量が多く、Fold Change値が負の整数であればポリスチレン製ディッシュの転写量が多いことになり、その絶対値が大きいほど、両者間での差が大きいことになる。
得られた結果を表1及び2に示す。
表1及び2の結果は、本発明の方法により培養された細胞が、上皮間葉転換誘導されたことを示唆するものである。
Claims (19)
- 接着型細胞を、脂環構造含有重合体成形体と接触した状態で培養する工程を有する、浮遊培養に馴化した接着型細胞の調製方法。
- 前記接着型細胞が、外来遺伝子を発現する遺伝子組み換えされた接着型細胞である、請求項1に記載の接着型細胞の調製方法。
- 前記外来遺伝子がタンパク質をコードする遺伝子である、請求項2に記載の接着型細胞の調製方法。
- 前記接着型細胞が動物由来の細胞である、請求項1~3のいずれかに記載の接着型細胞の調製方法。
- 前記動物由来の細がCHO細胞である、請求項4に記載の接着型細胞の調製方法。
- 請求項1~5のいずれかに記載の接着型細胞の調製方法により、前記浮遊培養に馴化した接着型細胞を培養することによる、外来遺伝子によってコードされた核酸又はタンパク質の生産方法。
- 脂環構造含有重合体成形体からなる接着型細胞の浮遊培養馴化促進剤。
- 接着型細胞を液体培地中に浮遊培養に馴化させるための、脂環構造含有重合体成形体の使用。
- 少なくとも底面が脂環構造含有重合体成形体からなるものである接着型細胞の浮遊培養馴化用容器。
- 前記脂環構造含有重合体が飽和ノルボルネン系重合体である、請求項9に記載の浮遊培養馴化用容器。
- 接着型上皮細胞を、脂環構造含有重合体成形体と接触した状態で培養する工程を有する、上皮間葉転換の誘導方法。
- 前記接着型上皮細胞が、外来遺伝子を発現する遺伝子組み換えされた接着型細胞である、請求項11に記載の上皮間葉転換の誘導方法。
- 前記接着型上皮細胞が動物由来の細胞である、請求項11または12に記載の上皮間葉転換の誘導方法。
- 前記動物由来の細胞がCHO細胞である、請求項13に記載の上皮間葉転換の誘導方法。
- 請求項12~14のいずれかに記載の上皮間葉転換の誘導方法により、上皮間葉転換した接着型細胞を培養することによる、外来遺伝子によってコードされた核酸又はタンパク質の生産方法。
- 脂環構造含有重合体成形体からなる接着型上皮細胞の上皮間葉転換誘導剤。
- 接着型上皮細胞を上皮間葉転換誘導させるための、脂環構造含有重合体成形体の使用。
- 少なくとも底面が脂環構造含有重合体成形体からなるものである接着型上皮細胞の上皮間葉転換誘導用容器。
- 前記脂環構造含有重合体が飽和ノルボルネン系重合体である、請求項18に記載の上皮間葉転換誘導用容器。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201680071272.8A CN108291198A (zh) | 2015-12-18 | 2016-12-16 | 悬浮培养驯化粘附型细胞的制备方法、粘附型上皮细胞的上皮间叶转化诱导方法及其利用 |
US15/781,250 US20180355321A1 (en) | 2015-12-18 | 2016-12-16 | Method for preparing adherent-type cells acclimated to suspension culture, method for inducing epithelial-mesenchymal transition in adherent-type epithelial cells, and use for methods |
JP2017556475A JP6988480B2 (ja) | 2015-12-18 | 2016-12-16 | 浮遊培養馴化接着型細胞の調製方法、接着型上皮細胞の上皮間葉転換誘導方法、及びそれらの利用 |
EP16875795.3A EP3392334A4 (en) | 2015-12-18 | 2016-12-16 | PROCESS FOR PREPARING ACCLIMATE CELL ACCLIMATE TO SUSPENDED CULTURE, METHOD FOR INDUCING EPITHELYEMESENCHYMAL TRANSITION FOR ADHERENT EPITHELIAL CELL, AND APPLYING THESE METHODS |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015247270 | 2015-12-18 | ||
JP2015-247270 | 2015-12-18 | ||
JP2016211700 | 2016-10-28 | ||
JP2016-211700 | 2016-10-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017104821A1 true WO2017104821A1 (ja) | 2017-06-22 |
Family
ID=59056671
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2016/087606 WO2017104821A1 (ja) | 2015-12-18 | 2016-12-16 | 浮遊培養馴化接着型細胞の調製方法、接着型上皮細胞の上皮間葉転換誘導方法、及びそれらの利用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20180355321A1 (ja) |
EP (1) | EP3392334A4 (ja) |
JP (1) | JP6988480B2 (ja) |
CN (1) | CN108291198A (ja) |
WO (1) | WO2017104821A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020066396A1 (ja) * | 2018-09-28 | 2020-04-02 | 日本ゼオン株式会社 | 心毒性評価方法 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH029388A (ja) | 1988-03-09 | 1990-01-12 | Ajinomoto Co Inc | 生理活性タンパク質の製造法 |
JP2005073509A (ja) | 2003-08-28 | 2005-03-24 | Nihon Pharmaceutical Co Ltd | ヒトアンチトロンビンの生産方法 |
WO2006101925A2 (en) | 2005-03-16 | 2006-09-28 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
WO2012081629A1 (ja) * | 2010-12-15 | 2012-06-21 | 大学共同利用機関法人情報・システム研究機構 | タンパク質の生産方法 |
WO2014038025A1 (ja) * | 2012-09-05 | 2014-03-13 | Scivax株式会社 | 細胞の上皮性維持に作用する物質のスクリーニング方法 |
WO2014138455A1 (en) * | 2013-03-07 | 2014-09-12 | California Stem Cell, Inc. | Individualized high purity hepatocellular carcinoma stem cells, methods and use of the same |
WO2015199119A1 (ja) * | 2014-06-26 | 2015-12-30 | 日本ゼオン株式会社 | 接着型細胞の培養方法、培養容器およびタンパク質の産生方法 |
WO2015199117A1 (ja) * | 2014-06-26 | 2015-12-30 | 日本ゼオン株式会社 | 培養細胞の分化促進方法および培養細胞分化促進剤 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7858044B2 (en) * | 2003-04-30 | 2010-12-28 | Nexus Biosystems, Inc. | Multi-well plate providing a high-density storage and assay platform |
JP2009106160A (ja) * | 2007-10-26 | 2009-05-21 | Nipro Corp | 細胞培養容器及び細胞培養方法 |
JP5024004B2 (ja) * | 2007-12-03 | 2012-09-12 | ニプロ株式会社 | 付着性細胞培養容器及び付着性細胞の培養方法 |
CN104039949B (zh) * | 2011-12-28 | 2020-09-08 | Jsr株式会社 | 细胞粘附抑制剂 |
WO2014028274A1 (en) * | 2012-08-15 | 2014-02-20 | California Stem Cell, Inc. | Rapid method production high purity cancer stem cells and population of high purity cancer stem cells |
-
2016
- 2016-12-16 EP EP16875795.3A patent/EP3392334A4/en not_active Withdrawn
- 2016-12-16 JP JP2017556475A patent/JP6988480B2/ja active Active
- 2016-12-16 US US15/781,250 patent/US20180355321A1/en not_active Abandoned
- 2016-12-16 CN CN201680071272.8A patent/CN108291198A/zh active Pending
- 2016-12-16 WO PCT/JP2016/087606 patent/WO2017104821A1/ja active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH029388A (ja) | 1988-03-09 | 1990-01-12 | Ajinomoto Co Inc | 生理活性タンパク質の製造法 |
JP2005073509A (ja) | 2003-08-28 | 2005-03-24 | Nihon Pharmaceutical Co Ltd | ヒトアンチトロンビンの生産方法 |
WO2006101925A2 (en) | 2005-03-16 | 2006-09-28 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
WO2012081629A1 (ja) * | 2010-12-15 | 2012-06-21 | 大学共同利用機関法人情報・システム研究機構 | タンパク質の生産方法 |
WO2014038025A1 (ja) * | 2012-09-05 | 2014-03-13 | Scivax株式会社 | 細胞の上皮性維持に作用する物質のスクリーニング方法 |
WO2014138455A1 (en) * | 2013-03-07 | 2014-09-12 | California Stem Cell, Inc. | Individualized high purity hepatocellular carcinoma stem cells, methods and use of the same |
WO2015199119A1 (ja) * | 2014-06-26 | 2015-12-30 | 日本ゼオン株式会社 | 接着型細胞の培養方法、培養容器およびタンパク質の産生方法 |
WO2015199117A1 (ja) * | 2014-06-26 | 2015-12-30 | 日本ゼオン株式会社 | 培養細胞の分化促進方法および培養細胞分化促進剤 |
Non-Patent Citations (5)
Title |
---|
KI C.S. ET AL.: "Thiol-ene hydrogels as desmoplasia-mimetic matrices for modeling pancreatic cancer cell growth, invasion, and drug resistance", BIOMATERIALS, vol. 35, 2014, pages 9668 - 9677, XP029055289, DOI: doi:10.1016/j.biomaterials.2014.08.014 * |
MASSAGUE J, CELL, vol. 134, July 2008 (2008-07-01), pages 215 - 230 |
RAZA A. ET AL.: "The influence of matrix properties on growth and morphogenesis of human pancreatic ductal epithelial cells in 3D", BIOMATERIALS, vol. 34, 2013, pages 5117 - 5127, XP028593862, DOI: doi:10.1016/j.biomaterials.2013.03.086 * |
See also references of EP3392334A4 |
TOKUZO ARAO ET AL.: "EMT Kenkyu", MOLECULAR TARGETED THERAPY FOR CANCER, vol. 9, no. 1, 2011, pages 61 - 64 * |
Also Published As
Publication number | Publication date |
---|---|
EP3392334A4 (en) | 2019-10-30 |
US20180355321A1 (en) | 2018-12-13 |
JP6988480B2 (ja) | 2022-01-05 |
EP3392334A1 (en) | 2018-10-24 |
CN108291198A (zh) | 2018-07-17 |
JPWO2017104821A1 (ja) | 2018-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102470046B1 (ko) | 접착형 세포의 배양 방법, 배양 용기 및 단백질의 생산 방법 | |
JP6580221B2 (ja) | 医療器具、細胞培養方法およびフッ素含有環状オレフィンポリマー組成物 | |
CN106661546B (zh) | 培养细胞的分化促进方法以及培养细胞分化促进剂 | |
KR101965998B1 (ko) | 의료 기구, 불소 함유 환상 올레핀 폴리머, 불소 함유 환상 올레핀 폴리머 조성물, 및 세포 배양 방법 | |
WO2017104821A1 (ja) | 浮遊培養馴化接着型細胞の調製方法、接着型上皮細胞の上皮間葉転換誘導方法、及びそれらの利用 | |
JP2018201403A (ja) | 幹細胞の培養方法 | |
JP6716887B2 (ja) | 接着型細胞の培養方法、及びタンパク質の産生方法 | |
JP5958658B2 (ja) | 培養細胞内のerkまたはaktのリン酸化亢進方法、細胞の培養方法、およびリン酸化亢進剤 | |
JP6973082B2 (ja) | 接着型細胞の培養方法 | |
TWI727925B (zh) | 貼附型細胞的培養方法、培養容器及蛋白質的產生方法 | |
JP6806058B2 (ja) | 細胞外マトリックス産生促進方法、細胞の培養方法、及び細胞外マトリックス産生促進剤 | |
JP2018201394A (ja) | 細胞シートの製造方法 | |
JPWO2018066512A1 (ja) | 幹細胞の分離方法、分化誘導方法及び細胞培養容器の使用 | |
WO2022163653A1 (ja) | ベクター、ベクターが導入された組み換え脊椎動物細胞およびその製造方法、並びに、標的タンパク質の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16875795 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017556475 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2016875795 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2016875795 Country of ref document: EP Effective date: 20180718 |